Table 1 Demographic, clinical, anatomopathological characteristics and PCR data from patients with high-risk prostate cancer (needle biopsies) and normal prostate controls (cytoprostatectomies)
From: The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness
Parameter | Overall | NP | PCa |
|---|---|---|---|
Age, Median (IQR) | 76 (68.2–81.7) | 70 (61.5–81) | 78 (69–81.7) |
PSA level, ng/ml, median (IQR) |  |  | 54.5 (37.2–212) |
BMI, median (IQR) | 27.6 (25.4–30.3) | 25.8 (24.4–32.5) | 27.9 (25.5–30.1) |
Gleason score | |||
 = 7 | - | - | 18/52 (35%) |
 > 7 | - | - | 34/52 (65%) |
Extraprostatic extension | - | - | 18/52 (35%) |
Perineural infiltration | - | - | 27/52 (52%) |
% of samples where mRNA expression was detected: | |||
 Ghrelin | 56/64 (87,5%) | 9/12 (83,3%) | 47/52 (90%) |
 In1-ghrelin | 54/64 (84,5%) | 8/12 (66,6%) | 46/52 (88,5%) |
 GHSR-1a | 1/27 (3,7%) | 0/7 (0%) | 1/20 (5%) |
 GHSR-1b | 7/28 (25,5%) | 2/8 (25%) | 5/20 (20%) |